{"pmid":32340389,"title":"Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.","text":["Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study.","The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M(pr)) provides a highly validated pharmacological target for the discovery and design of inhibitors. We identified potent M(pr) inhibitors employing computational techniques that entail the screening of a Marine Natural Product (MNP) library. MNP library was screened by a hyphenated pharmacophore model, and molecular docking approaches. Molecular dynamics and re-docking further confirmed the results obtained by structure-based techniques and allowed this study to highlight some crucial aspects. Seventeen potential SARS-CoV-2 M(pr) inhibitors have been identified among the natural substances of marine origin. As these compounds were extensively validated by a consensus approach and by molecular dynamics, the likelihood that at least one of these compounds could be bioactive is excellent.","Mar Drugs","Gentile, Davide","Patamia, Vincenzo","Scala, Angela","Sciortino, Maria Teresa","Piperno, Anna","Rescifina, Antonio","32340389"],"abstract":["The current emergency due to the worldwide spread of the COVID-19 caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a great concern for global public health. Already in the past, the outbreak of severe acute respiratory syndrome (SARS) in 2003 and Middle Eastern respiratory syndrome (MERS) in 2012 demonstrates the potential of coronaviruses to cross-species borders and further underlines the importance of identifying new-targeted drugs. An ideal antiviral agent should target essential proteins involved in the lifecycle of SARS-CoV. Currently, some HIV protease inhibitors (i.e., Lopinavir) are proposed for the treatment of COVID-19, although their effectiveness has not yet been assessed. The main protease (M(pr)) provides a highly validated pharmacological target for the discovery and design of inhibitors. We identified potent M(pr) inhibitors employing computational techniques that entail the screening of a Marine Natural Product (MNP) library. MNP library was screened by a hyphenated pharmacophore model, and molecular docking approaches. Molecular dynamics and re-docking further confirmed the results obtained by structure-based techniques and allowed this study to highlight some crucial aspects. Seventeen potential SARS-CoV-2 M(pr) inhibitors have been identified among the natural substances of marine origin. As these compounds were extensively validated by a consensus approach and by molecular dynamics, the likelihood that at least one of these compounds could be bioactive is excellent."],"journal":"Mar Drugs","authors":["Gentile, Davide","Patamia, Vincenzo","Scala, Angela","Sciortino, Maria Teresa","Piperno, Anna","Rescifina, Antonio"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340389","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.3390/md18040225","keywords":["covid-19","sars-cov-2","docking","marine natural product","virtual screening"],"e_drugs":["Lopinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1665351883959566336,"score":8.574329,"similar":[{"pmid":32210741,"pmcid":"PMC7081067","title":"Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.","text":["Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target.","Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect. Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease. Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated. Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features. Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses. Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2.","EXCLI J","Ortega, Joseph Thomas","Serrano, Maria Luisa","Pujol, Flor Helene","Rangel, Hector Rafael","32210741"],"abstract":["Direct-acting antivirals are effective tools to control viral infections. SARS-CoV-2 is a coronavirus associated with the epidemiological outbreak in late 2019. Previous reports showed that HIV-1 protease inhibitors could block SARS-CoV main protease. Based on that and using an in silico approach, we evaluated SARS-CoV-2 main protease as a target for HIV-1 protease inhibitors to reveal the structural features related to their antiviral effect. Our results showed that several HIV inhibitors such as lopinavir, ritonavir, and saquinavir produce strong interaction with the active site of SARS-CoV-2 main protease. Furthermore, broad library protease inhibitors obtained from PubChem and ZINC (www.zinc.docking.org) were evaluated. Our analysis revealed 20 compounds that could be clustered into three groups based on their chemical features. Then, these structures could serve as leading compounds to develop a series of derivatives optimizing their activity against SARS-CoV-2 and other coronaviruses. Altogether, the results presented in this work contribute to gain a deep understanding of the molecular pharmacology of SARS-CoV-2 treatment and validate the use of protease inhibitors against SARS-CoV-2."],"journal":"EXCLI J","authors":["Ortega, Joseph Thomas","Serrano, Maria Luisa","Pujol, Flor Helene","Rangel, Hector Rafael"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32210741","week":"202013|Mar 23 - Mar 29","doi":"10.17179/excli2020-1189","keywords":["coronavirus","hiv","sars-cov-2","protease","treatment"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Ritonavir","Saquinavir","Lopinavir"],"_version_":1664638933395308545,"score":273.68246},{"pmid":32238094,"title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","text":["Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer","32238094"],"abstract":["Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238094","week":"202014|Mar 30 - Apr 05","doi":"10.1080/07391102.2020.1751298","keywords":["3clpro","md simulation","sars-cov-2","corona virus","drug repurposing","remdesivir","virtual screening"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China","Chymotrypsin","Chymotrypsin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["flavone","remdesivir","Coumarins","Darunavir","Saquinavir"],"_version_":1664638354245812224,"score":236.40958},{"pmid":32162456,"title":"Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","text":["Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.","The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community.","Mol Inform","Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem","32162456"],"abstract":["The recently emerged 2019 Novel Coronavirus (SARS-CoV-2) and associated COVID-19 disease cause serious or even fatal respiratory tract infection and yet no approved therapeutics or effective treatment is currently available to effectively combat the outbreak. This urgent situation is pressing the world to respond with the development of novel vaccine or a small molecule therapeutics for SARS-CoV-2. Along these efforts, the structure of SARS-CoV-2 main protease (Mpro) has been rapidly resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Recently, our group has developed a novel deep learning platform - Deep Docking (DD) which provides fast prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual screening of billions of purchasable molecules in a short time. In the current study we applied DD to all 1.3 billion compounds from ZINC15 library to identify top 1,000 potential ligands for SARS-CoV-2 Mpro protein. The compounds are made publicly available for further characterization and development by scientific community."],"journal":"Mol Inform","authors":["Ton, Anh-Tien","Gentile, Francesco","Hsing, Michael","Ban, Fuqiang","Cherkasov, Artem"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32162456","week":"202011|Mar 09 - Mar 15","doi":"10.1002/minf.202000028","keywords":["covid-19","sars-cov-2","deep learning","protease inhibitors","virtual screening"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664640874780295169,"score":212.08276},{"pmid":32266873,"title":"Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.","text":["Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.","The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has resulted in an unprecedented number of infected people. The highly contagious nature of this virus makes it imperative for us to identify promising inhibitors from pre-existing antiviral drugs. Two druggable targets, namely 3C-like proteinase (3CLpro) and 2'-O-ribose methyltransferase (2'-O-MTase) were selected in this study due to their indispensable nature in the viral life cycle. 3CLpro is a cysteine protease responsible for the proteolysis of replicase polyproteins resulting in the formation of various functional proteins, whereas 2'-O-MTase methylates the ribose 2'-O position of the first and second nucleotide of viral mRNA, which sequesters it from the host immune system. The selected drug target proteins were screened against an in-house library of 123 antiviral drugs. Two promising drug molecules were identified for each protein based on their estimated free energy of binding (DeltaG), the orientation of drug molecules in the active site and the interacting residues. The selected protein-drug complexes were then subjected to MD simulation, which consists of various structural parameters to equivalently reflect their physiological state. From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (DeltaG = -9.8 kcal/mol) & Raltegravir (DeltaG = -7.8 kcal/mol) for 3CLpro and Dolutegravir (DeltaG = -9.4 kcal/mol) and Bictegravir (DeltaG = -8.4 kcal/mol) for 2'-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2. Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Khan, Rameez Jabeer","Jha, Rajat Kumar","Amera, Gizachew Muluneh","Jain, Monika","Singh, Ekampreet","Pathak, Amita","Singh, Rashmi Prabha","Muthukumaran, Jayaraman","Singh, Amit Kumar","32266873"],"abstract":["The recent pandemic associated with SARS-CoV-2, a virus of the Coronaviridae family, has resulted in an unprecedented number of infected people. The highly contagious nature of this virus makes it imperative for us to identify promising inhibitors from pre-existing antiviral drugs. Two druggable targets, namely 3C-like proteinase (3CLpro) and 2'-O-ribose methyltransferase (2'-O-MTase) were selected in this study due to their indispensable nature in the viral life cycle. 3CLpro is a cysteine protease responsible for the proteolysis of replicase polyproteins resulting in the formation of various functional proteins, whereas 2'-O-MTase methylates the ribose 2'-O position of the first and second nucleotide of viral mRNA, which sequesters it from the host immune system. The selected drug target proteins were screened against an in-house library of 123 antiviral drugs. Two promising drug molecules were identified for each protein based on their estimated free energy of binding (DeltaG), the orientation of drug molecules in the active site and the interacting residues. The selected protein-drug complexes were then subjected to MD simulation, which consists of various structural parameters to equivalently reflect their physiological state. From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (DeltaG = -9.8 kcal/mol) & Raltegravir (DeltaG = -7.8 kcal/mol) for 3CLpro and Dolutegravir (DeltaG = -9.4 kcal/mol) and Bictegravir (DeltaG = -8.4 kcal/mol) for 2'-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2. Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Khan, Rameez Jabeer","Jha, Rajat Kumar","Amera, Gizachew Muluneh","Jain, Monika","Singh, Ekampreet","Pathak, Amita","Singh, Rashmi Prabha","Muthukumaran, Jayaraman","Singh, Amit Kumar"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266873","week":"202015|Apr 06 - Apr 12","doi":"10.1080/07391102.2020.1753577","keywords":["2'-o-ribose methyltransferase","3c-like proteinase","drug repurposing","md simulation","sars-cov-2","docking"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ribose","ABT-450","bictegravir","Raltegravir Potassium","dolutegravir"],"_version_":1664637636106518528,"score":211.87717},{"pmid":32278693,"title":"In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.","text":["In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.","AIMS: The severe acute respiratory syndrome coronavirus 2, better known as COVID-19 has become the current health concern to the entire world. Initially appeared in Wuhan, China around December 2019, it had spread to almost 187 countries due to its high contagious nature. Precautionary measures remain the sole obliging tactic to cease the person to person transmissions till any effective method of treatment or vaccine is developed. Amidst the pandemic, research and development of new molecule is labour-intensive and tedious process. Drug repurposing is the concept of identifying therapeutically potent molecule from the library of pre-existing molecules. MATERIALS AND METHODS: In the present study, 61 molecules that are already being used in clinics or under clinical scrutiny as antiviral agents are surveyed via docking study. Docking study was performed using Maestro interface (Schrodinger Suite, LLC, NY). KEY FINDINGS: Out of these 61 molecules, 37 molecules were found to interact with >2 protein structures of COVID-19. The docking results indicate that amongst the reported molecules, HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed promising features of binding to COVID-19 enzyme. Along with these, Methisazone an inhibitor of protein synthesis, CGP42112A an angiotensin AT2 receptor agonist and ABT450 an inhibitor of the non-structural protein 3-4A might become convenient treatment option as well against COVID-19. SIGNIFICANCE: The drug repurposing approach provide an insight about the therapeutics that might be helpful in treating corona virus disease.","Life Sci","Shah, Bhumi","Modi, Palmi","Sagar, Sneha R","32278693"],"abstract":["AIMS: The severe acute respiratory syndrome coronavirus 2, better known as COVID-19 has become the current health concern to the entire world. Initially appeared in Wuhan, China around December 2019, it had spread to almost 187 countries due to its high contagious nature. Precautionary measures remain the sole obliging tactic to cease the person to person transmissions till any effective method of treatment or vaccine is developed. Amidst the pandemic, research and development of new molecule is labour-intensive and tedious process. Drug repurposing is the concept of identifying therapeutically potent molecule from the library of pre-existing molecules. MATERIALS AND METHODS: In the present study, 61 molecules that are already being used in clinics or under clinical scrutiny as antiviral agents are surveyed via docking study. Docking study was performed using Maestro interface (Schrodinger Suite, LLC, NY). KEY FINDINGS: Out of these 61 molecules, 37 molecules were found to interact with >2 protein structures of COVID-19. The docking results indicate that amongst the reported molecules, HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed promising features of binding to COVID-19 enzyme. Along with these, Methisazone an inhibitor of protein synthesis, CGP42112A an angiotensin AT2 receptor agonist and ABT450 an inhibitor of the non-structural protein 3-4A might become convenient treatment option as well against COVID-19. SIGNIFICANCE: The drug repurposing approach provide an insight about the therapeutics that might be helpful in treating corona virus disease."],"journal":"Life Sci","authors":["Shah, Bhumi","Modi, Palmi","Sagar, Sneha R"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278693","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.lfs.2020.117652","keywords":["antiviral drugs","covid-19","corona virus","docking studies","mers-cov","sars-cov-2"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["ABT-450","Methisazone"],"_version_":1664636873230778368,"score":211.63603}]}